ClinicalTrials.gg
CompletedNCT07601958Updated May 22, 2026

Management of Acute Complicated Diverticulitis: An Assessment of Current Practices

An observational study in Acute Complicated Diverticulitis and Colonic Diverticulitis, sponsored by Jules Bordet Institute. Completed at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Jules Bordet Institute · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
208
Ages
18 Years and older
Sex
All
01

Study summary

Acute complicated diverticulitis (ACD) is a frequent surgical emergency that can be life-threatening. It encompasses various clinical entities, including colonic perforations, abscesses (Hinchey II), fistulas, and purulent or fecal peritonitis (Hinchey III/IV). Historically, the Hartmann procedure (HP) was established as the standard of care for diffuse peritonitis, particularly in frail patients. However, this intervention is associated with high rates of permanent stomas, long-term complications, and impaired quality of life. Over the past decade, several randomized controlled trials (RCTs) have compared HP with sigmoid resection and primary anastomosis (PA), sometimes combined with a diverting ileostomy. Results from these studies, notably the LADIES and DIVERTI trials, indicate that in hemodynamically stable and immunocompetent patients, PA is associated with superior functional outcomes, fewer late complications, and higher stoma reversal rates. Other minimally invasive approaches, such as laparoscopic peritoneal lavage for Hinchey III, have also been explored, showing promise in reducing stomas and reinterventions. However, their efficacy relies on stringent patient selection, and their use is not recommended by current guidelines (e.g., HAS 2017) due to higher reintervention rates. Recent epidemiological data suggest a trend toward reducing emergency surgical interventions in favor of more conservative strategies in selected cases, such as initial medical management followed by elective surgery. In this context of diversifying therapeutic options, choosing the optimal treatment requires a delicate balance between efficacy, morbidity, mortality, quality of life, and long-term preservation of intestinal function. Despite these advances, several questions remain, particularly regarding patient selection criteria and the real-world long-term impact of these interventions. A potentially underestimated factor is the role of the operator, as a significant portion of emergency cases (nights and weekends) are handled by surgeons in training.

Primary Objective: To provide a comprehensive overview of current management strategies for acute complicated diverticulitis by identifying preferred therapeutic modalities (conservative management, emergency surgery, delayed surgery) at the HUB (Hôpital Universitaire de Bruxelles).

Secondary Objectives: To evaluate the adherence of these therapeutic approaches to international guidelines. To identify clinical and context-specific predictive factors influencing the choice of therapeutic strategy.

02

Conditions studied

  • Acute Complicated Diverticulitis
  • Colonic Diverticulitis
03

In context

Diverticulitis, Colonic

27 studies on the registry are indexed under Diverticulitis, Colonic; 8 are open to participants now.

This study's enrollment of 208 is below the median of 250 across 15 observational studies indexed under Diverticulitis, Colonic.

Browse Diverticulitis, Colonic studies →

Lead sponsor

Jules Bordet Institute is the lead sponsor of 106 studies on the registry; 27 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients older than 18 years who were treated for acute complicated diverticulitis between January 1, 2015 and December 31, 2024 at Erasme Hospital and Institut Jules Bordet.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients presenting with a first episode or recurrence of acute complicated diverticulitis.
  • CT scan confirmation of a Hinchey stage ≥ Ib (including stages Ib, II, III, and IV) at admission.
  • Initial management performed within the HUB (Hôpital Universitaire de Bruxelles) network.
  • Hospital admission between January 1, 2015, and December 31, 2024.

Exclusion criteria

Exclusion Criteria:

  • Uncomplicated acute diverticulitis, defined by a CT scan Hinchey stage of 0 or Ia.
  • Patients in whom the diagnosis of acute diverticulitis was ultimately ruled out during medical chart review.
  • Patients whose initial management occurred at another hospital facility (outside the HUB network).
  • Incomplete medical records preventing the reliable extraction of clinical or follow-up data.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
208 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Distribution of management strategies for acute complicated diverticulitis.

    Percentage of patients treated by each of the following strategies: exclusive medical treatment, radiological drainage, immediate emergency surgery, rescue surgery following medical failure, or elective surgery.

    Time frame: From hospital admission up to 10 years (end of study period).

Secondary outcomes

  1. Surgical Procedure Type (Hartmann Procedure vs. Primary Anastomosis) based on Hinchey Classification and Clinical Status.

    The study will evaluate the association between baseline clinical parameters (including age and immunosuppression status) and radiological severity, assessed by the Hinchey classification (stages Ib to IV on admission CT scan), with the final therapeutic choice. Logistic regression analysis will be used to identify independent predictors for: (1) failure of conservative treatment and (2) selection of surgical procedure type (Hartmann Procedure vs. Primary Anastomosis). Results will be reported as Odds Ratios (OR) with 95% Confidence Intervals.

    Time frame: Through study completion, an average of 14 days (duration of index hospitalization).

  2. Success rate of conservative treatment for complicated diverticulitis.

    Proportion of patients successfully managed without surgery during the index hospitalization.

    Time frame: During index hospitalization (average of 12.4 days).

  3. Post-operative morbidity and mortality.

    Percentage of patients with severe complications (Clavien-Dindo III-IV) and mortality rate at 30 days post-surgery.

    Time frame: 30 days post-surgery.

  4. Stoma reversal rate.

    Percentage of patients who received a temporary stoma and successfully underwent surgical restoration of bowel continuity during the follow-up period.

    Time frame: Up to 10 years.

  5. Evolution of the Rate of Laparoscopic Approach.

    Percentage of patients undergoing a laparoscopic approach (including converted laparoscopies) compared to open surgery. The trend will be analyzed across three time periods (2015-2017, 2018-2020, 2021-2024) to assess the adoption of minimally invasive techniques.

    Time frame: Perioperative (during initial surgery).

  6. Length of Hospital Stay (LOS).

    Number of days from hospital admission to discharge. The median length of stay will be compared across the three time periods (2015-2017, 2018-2020, 2021-2024) to evaluate the impact of changing clinical practices.

    Time frame: From hospital admission to discharge (average 10-14 days).

  7. Adherence to Guidelines Regarding Peritoneal Lavage.

    Percentage of surgical cases where peritoneal lavage was performed as a standalone treatment (without resection). The evolution of this practice will be assessed across the three time periods to evaluate adherence to international guidelines (EAES/WSES) recommending the abandonment of this technique.

    Time frame: Perioperative (during initial surgery).

07

Study locations

1 site
  • Institut Jules Bordet
    Anderlecht, Brussels Capital 1070, Belgium
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared in order to protect patient confidentiality and comply with European data protection regulations (GDPR) and institutional privacy policies.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2025 to primary completion in Mar 2026, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2026
First posted
May 22, 2026
StartActual
Dec 1, 2025
Primary completionActual
Mar 30, 2026
CompletionActual
Mar 30, 2026
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07601958
Responsible party
Gabriel Liberale (Professor, Jules Bordet Institute) — Principal investigator
First posted
May 22, 2026
Start date
Dec 1, 2025
Primary completion
Mar 30, 2026
Completion
Mar 30, 2026
Last update
May 22, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion